Catalyst Pharmaceuticals
Mark Hardison CPIM-F, CSCP-F, CLTD-F is an accomplished supply chain professional with extensive experience in manufacturing and logistics. Currently serving as Director of Manufacturing at Catalyst Pharmaceuticals, Inc., Mark previously held various significant roles, including Materials Manager at Mallinckrodt Pharmaceuticals and Associate Director of Supply Chain at Jubilant Pharmaceuticals. Mark has been actively involved in industry education and certification through APICS, contributing as a founding member and chair of various examination committees. Additionally, Mark has leadership experience in multiple companies including Fleet Laboratories and Banner Pharmacaps, overseeing operations and driving successful supply chain strategies. Mark holds a Bachelor of Business Administration in Management from Strayer University-Maryland.
This person is not in the org chart
This person is not in any teams
Catalyst Pharmaceuticals
2 followers
Catalyst Pharmaceuticals is a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel high-quality medicines for patients living with rare diseases. With exceptional patient focus, Catalyst is committed to developing a robust pipeline of cutting-edge, first- or best-in-class medicines for other rare diseases. Catalyst's New Drug Application for FIRDAPSE® (amifampridine) Tablets 10 mg for the treatment of adults with Lambert-Eaton myasthenic syndrome ("LEMS") was approved in 2018 by the U.S. Food & Drug Administration ("FDA"), and FIRDAPSE is commercially available in the United States as a treatment for adults with LEMS. Further, Canada's national healthcare regulatory agency, Health Canada, has approved the use of FIRDAPSE for the treatment of adult patients in Canada with LEMS.